Have just tried to listen to it. It's in the process of being archived, so was jumping around and only got parts.
One piece of excellent news came yesterday, I think Alan said, of FDA approval of the Unifill Tuberculin.
Everything is on-track as previously stated for moving into Cross Farm in December.
Have been reviewing budgets and see no significant increases next year. They have to have the people in place, trained, and the planning in place in order to be able to meet expected demand, and this has been achieved on time, on budget.
A question came about R&D showing an increase to $1 million. This is principally due to moving product design and development in-house, after having used external sources for several years. Partly to maintain the IP assett moving forward, but also to transition and develop in-house design expertise to carry us into the future.
"We have a number of REALLY exciting products in the pipeline, Unifill Select being one, many related to drug delivery moving into collaboration with the pharmaceutical companies who we are currently in discusssions with."
Discussions with potential pharma partners are accelerating as these companies see the window of opportunity becoming increasingly limited re gaining access to Unilife technology.
In closing Alan said, "All the key elements of our business are now in place. We look forward to announcing further updates in the near future."
Sorry this is incomplete, will get further into it when I can. But all-in-all very upbeat and bullish about next year and beyond.
UNS Price at posting:
$1.00 Sentiment: Buy Disclosure: Held
